InnovaCare Health, as a Medicaid and Medicare Advantage company, provides services related to healthcare in Puerto Rico. InnovaCare’s Chief Administrative Officer, Penelope Kokkinides, recently discussed healthcare legislation with Donald Trump and Seema Verma, CMS Director. The meeting took place April 6, 2017, at the White House. Earlier on March 22, they held a Women in Healthcare Panel that was a roundtable discussion in the Roosevelt Room of the White House.
In the course of the meeting with President Trump and Director Verma, Kokkinides, one of eight women invited to the panel, pointed to the importance of increased funding for the Medicare Advantage program in Puerto Rico. Kokkinides noted that Puerto Rico has, since 2011, endured cuts of over $1-billion in federal funding to the Medicare Advantage program — cuts that are disproportionately severe compared to cuts made to the same program in the U.S.
Kokkinides noted that the administration, under the auspices of the CMS, is considering increased payments to Puerto Rico’s Medicare Advantage system. She expressed hope that the U.S. would do what is right for Puerto Rico. She drew attention to the possibility that failure to adequately fund Puerto Rico’s Medicare Advantage system could result in significant emigration to the U.S. That, Kokkinides pointed out, would raise the cost per individual 3-4 times because of higher healthcare costs in the U.S. She said that that reality made helping Puerto Rico not only the right thing to do but the financially responsible solution.
The Medicare Advantage program is the most popular healthcare plan in Puerto Rico. InnovaCare Health alone provides healthcare benefits to over 560,000 Puerto Ricans.
Penelope Kokkinides has over 20-years experience in managed-care systems such as Medicare and Medicaid. Penelope has extensive executive experience, including:
- Corporate VP for Care Management and Disease Management at AmeriChoice (part of UnitedHealth Group)
InnovaCare Health is a provider of managed healthcare services in Puerto Rico. InnovaCare operates the two leading healthcare plans in Puerto Rico — PMC Medicare Choice, Inc., and
MMM Healthcare, Inc.
Dr. Sameer Jejurikar is a plastic surgeon who received his medical degree from the University of Michigan. After graduating, he began practicing his craft at Dallas Medical Center and at Pine Creek Medical Center.
At these two locations, Sameer is able to provide his patients with award-winning services. In 2012 he won the Most Compassionate Doctor Award.
Dr. Jejurikar is a member of the American Society of Plastic Surgeons, the American Society for Aesthetic Plastic Surgery and the Dallas Society of Plastic Surgeons. He has provided content for publications such as Plastic & Reconstructive Surgery, Aesthetic Surgery Journal, Journal of Surgical Research and others.
Dr. Jejurikar’s expertise consists of the ability to perform everything from tummy tucks to facial reconstruction surgery. He can perform procedures such as rhinoplasty and breast enlargement. His set of skills are able to accommodate those whose goal is to look a little younger or those who wish to change their look entirely.
Jejurikar works closely with his clients to educate them on the procedure they are about to have and schedules surgical planning. In most cases, several short surgeries are preferred over handling the entire procedure in one session.
Plastic surgery is not only for individuals who wish to improve their appearance, but it is for those that wish to once again resemble who they used to be. People who have been in disfiguring accidents may wish to consult a plastic surgeon. Plastic surgeons are experts in the field of bone reconstruction and replacement of tissue.
No matter your reason for deciding to have plastic surgery, Dr. Jejurikar will work with you to accommodate your every desire.
Electronic cigarettes smoking has become more popular recently because it is believed to be less harmful as compared to the conventional cigarettes. However, a new study published in Oncotarget has shown that the e-cigarettes cause damage to gum tissues making them no safer than regular ones. Unlike the previous perception that suggested the chemicals in cigarettes are responsible for the poor health effects, vapor from the e-cigarettes produce inflammation proteins that damage the cells leading to gum and oral disease. Fawad Javed, a post-doctoral student at Eastman Institute for Oral Health, said he learned that even the flavoring in the cigarettes causes a lot of harm Although, other flavors might be intense than others.
Nicotine is the culprit of gum and oral disease. The batteries, cartridge holding the liquid and the device for heating in the cigarette contains nicotine, flavoring, and other chemicals. Irfan Rahman, Ph.D. professor of Environmental Medicine at the URSM said the manufacturers need to disclose all the chemicals used in the manufacture. He also suggests more research be done to determine the extent of damage the e-cigarettes can cause to people’s health. Rahman had previously published a study he did on the effects of e-cigarette vapors and flavoring on lung cells and the pollution effects. Oncotarget is also available on Dove Press.
Oncotarget is a multidisciplinary journal and a subsidiary of the Impact Journals, with a mission of making scientific results rapid and available. The organization aims at fighting diseases by linking different fields, eliminating boundaries and making sure discoveries are quickly published. Oncotarget publishes online articles weekly and with special demand, the article can be printed.
Oncotarget has a team of great scientists led by Mikhail Blagosklonny who is the Editor-in-Chief. This team helps researchers to contribute to the advancement of science so that one-day illness will be a thing of the past. Mikhail is among the top Oncology researchers in the world and he is passionate about making the world disease free. He has made significant discoveries in cancer and aging effects and ways to reduce them. Oncotarget has a great person to set the pace to be able to achieve its goals. Follow Oncotarget journal on Twitter.